Moolec Science S.A. Form 6-K Summary
Business context and reporting period
Moolec Science S.A., a Luxembourg-based foreign private issuer, filed Form 6-K for July 2023 under Commission File No. 001-41586. The filing identifies unaudited interim condensed consolidated financial statements as of March 31, 2023 and June 30, 2022, and for the three- and nine-month periods ended March 31, 2023 and 2022.
Financial metrics
The supplied filing text contains only the Form 6-K cover page and exhibit list. It does not provide the underlying financial statements or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, assets, liabilities, or equity.
Material changes versus the prior comparable period
The filing indicates that comparative periods ended March 31, 2022 are included in Exhibit 99.1, but the supplied text does not include the results or a comparison with the prior period.
Guidance, outlook, risks, contingencies, and unusual items
The filing text does not provide guidance, management commentary, risk disclosures, contingencies, or unusual-item details.
Exhibit 99.2 contains ValoraSoy S.A.’s statement of assets acquired and liabilities assumed as of April 24, 2023. The supplied text does not provide the amounts or transaction details.
Important facts to verify
- Review Exhibit 99.1 for the March 31, 2023 interim financial statements and key performance metrics.
- Verify comparative results for the three- and nine-month periods ended March 31, 2022.
- Review Exhibit 99.2 for the assets acquired and liabilities assumed in the ValoraSoy transaction.
- Confirm cash balances, liquidity, debt, operating cash flow, and any going-concern or other risk disclosures in the underlying exhibits.